A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2011
10/13/2011	WO2011125917A1 Method for generating data set for integrated proteomics, integrated proteomics method using data set for integrated proteomics that is generated by the generation method, and method for identifying causative substance using same
10/13/2011	WO2011125763A1 Preventive and/or remedy for hand and foot syndrome
10/13/2011	WO2011125331A1 Metal salen complex derivative and process for production thereof
10/13/2011	WO2011124953A2 Controlled release pharmaceutical compositions of tapentadol
10/13/2011	US20110251244 Oral Dosage Form Containing A PDE 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidone As Excipient
10/13/2011	US20110251146 Topical antifungal composition
10/13/2011	US20110251134 Combination of (a) a dna toposomerase inhibitor and (b) an iap inhibitor
10/13/2011	US20110250703 Il1rl-1 as a cardiovascular disease marker and therapeutic target
10/13/2011	US20110250271 Spaced drug delivery system
10/13/2011	US20110250228 Compositions and Methods for Identifying and Targeting Cancer Cells of Alimentary Canal Origin
10/13/2011	US20110250194 Treatment with Anti-ErbB2 Antibodies
10/13/2011	US20110250142 Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome
10/13/2011	CA2832436A1 Controlled release pharmaceutical compositions of tapentadol
10/13/2011	CA2795350A1 Ire-1.alpha. inhibitors
10/12/2011	EP2374825A1 Photodynamic therapeutic agent showing accumulation of cell-specific functions
10/12/2011	EP2374478A1 Nsaids-induced gastrointestinal mucosal disorder alleviator and manufacturing method thereof
10/12/2011	EP2374464A2 HCV N3S-NS4A protease inhibition
10/12/2011	EP2374458A1 Combination of an ACE inhibitor and an NSAID for use in ameliorating cachexia/SIRS
10/12/2011	EP2374451A2 Histone deacetylase inhibitors (HDAC) that correct protein misfolding and uses thereof
10/12/2011	EP2374450A1 Flupentixol compositions
10/12/2011	EP2373344A1 Combined drug administration
10/12/2011	EP2373343A1 Immunocytokines for tumour therapy with chemotherapeutic agents
10/12/2011	EP2373328A2 Stroke-generated angiogenesis enhancers and uses thereof
10/12/2011	EP2373314A1 Use of eltoprazine for the treatment of l-dopa-induced dyskinesia
10/12/2011	EP2373309A1 Anticancer combination comprising docetaxel and an antisense oligonucleotide
10/12/2011	EP2373303A1 1-amino-alkylcyclohexane derivatives for the treatment of inflammatory skin diseases
10/12/2011	EP2373160A1 Topically active steroids for use in radiation and chemotherapeutics injury
10/12/2011	EP2019680B1 Augmentation of titer for vaccination in animals
10/12/2011	EP1448995B9 Assay for screening candidate drugs for the treatment of inflammatory diseases
10/12/2011	EP1385820B1 Anthranilic acid amides, method for the production thereof, their use as antiarrhythmia agents, and pharmaceutical preparations thereof
10/12/2011	EP1294377B1 Methods and compositions for the treatment of alcoholism and alcohol dependence
10/12/2011	EP1263471B1 Antimicrobial compounds and formulations
10/12/2011	CN1981761B Methods and compositions using immune regulative compound for treatment and management of cancers and other diseases
10/12/2011	CN1473265B Method for producing purified hematinic iron-saccharidic complex and product produced
10/12/2011	CN102216316A Substituted amine derivative and medicinal composition comprising same as the active ingredient
10/12/2011	CN102215872A Methods and compositions for the treatment of cancer
10/12/2011	CN102215871A Carbohydrate binding molecules
10/12/2011	CN102215870A Diagnosis method and therapeutic method for cancer
10/12/2011	CN102215833A Benzoquinone derivative e3330 in combination with chemotherapeutic agents for the treatment of cancer and angiogenesis
10/12/2011	CN102210866A Oral preparation for slowing down absorption of alpha-glycosidase inhibitor and enhancing hypoglycemic drug effect
10/12/2011	CN102210865A Concomitant pharmaceutical agents and use thereof
10/12/2011	CN102210864A Formula of medicament for treating non-infectious ocular inflammations, and inhibiting corneal neovascularization and anti-rejection reaction generated after corneal grafting
10/12/2011	CN102210658A Microcapsule soft capsule preparation with high alpha-linolenic acid content
10/12/2011	CN101721368B Medicinal composition for aerosol
10/12/2011	CN101217870B Antimicrobial compositions containing synergistic combinations of quaternary ammonium compounds and essential oils and/or constituents thereof
10/12/2011	CN101199847B Drug compound for AT1 receptor antagonist/diuretic/folate coupling and uses thereof
10/12/2011	CN101198326B Combined pharmaceutical preparation for treatment of type 2 diabetes
10/11/2011	US8034933 graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis; human immunodeficiency viricides
10/11/2011	US8034820 Pharmaceutical composition
10/11/2011	US8034799 Preventing and/or treating cardiovascular disease and/or associated heart failure
10/11/2011	US8034615 Method for treating autoimmune diseases and screening method for preventive or therapeutic agent for the same
10/11/2011	US8034389 Cranberry seed oil extract and compositions containing components thereof
10/11/2011	US8034378 water; a biodegradable microparticle of a polylactone, polyorthoester, a polyanhydride, or a polycyanoacrylate; an antigen adsorbed to the microparticle; and a phospholipid adjuvant with one or more phosphoric acid or phosphodiester groups and linear alkane groups
10/11/2011	CA2506930C Dosage forms containing a proton pump inhibitor, a nsaid, and a buffer
10/11/2011	CA2494100C Pyrazole compositions useful as inhibitors of gsk-3
10/11/2011	CA2465327C Nonhuman model animal of th2-mediated hyperimmune response
10/11/2011	CA2464322C Methods of treatment using a gastric retained gabapentin dosage
10/11/2011	CA2457840C Hdl for the treatment of stroke and other ischemic conditions
10/11/2011	CA2420537C A composition for treatment of parkinson's disease
10/11/2011	CA2400482C Bupropion metabolites and methods of their synthesis and use
10/11/2011	CA2394862C Tnf-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated disorder
10/11/2011	CA2390472C Anti-inflammatory actions of cytochrome p450 epoxygenase-derived eicosanoids
10/11/2011	CA2382177C Method of treating body insect infestation
10/11/2011	CA2325442C Treatment of cardiac hypertrophy using interferon-gamma
10/06/2011	WO2011123691A1 Perifosine and capecitabine as a combined treatment for cancer
10/06/2011	WO2011122947A1 Staining composition
10/06/2011	WO2011122701A1 Method for treating schizophrenia and related diseases
10/06/2011	WO2011122634A1 Prognostic method for pulmonary adenocarcinoma, pulmonary adenocarcinoma detection kit, and pharmaceutical composition for treating pulmonary adenocarcinoma
10/06/2011	WO2011122321A1 Agent for inhibiting physiological activity of heparin-binding protein
10/06/2011	WO2011121558A1 Combination therapy comprising a ccr5 antagonist, a hiv-1 protease inhibitor and a pharmacokinetic enhancer
10/06/2011	WO2011121496A1 Composition comprising insulin and herbal oil for transdermal or transmucosal administration
10/06/2011	WO2011121351A1 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
10/06/2011	WO2011121182A1 Pharmaceutical composition comprising gemfibrozil and cyp2c8 and/or oatp substrate drug such as repaglinide
10/06/2011	WO2011120930A1 Method for stimulating the reproductive capacity in a bull, and composition for stimulating the reproductive capacity in a bull
10/06/2011	WO2011120925A1 Parenteral pharmaceutical form which releases aromatse inhibitor and gestagens, for the treatment of endometriosis
10/06/2011	WO2011120923A1 Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
10/06/2011	WO2011120911A1 Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling
10/06/2011	WO2011120870A1 Egfr inhibitor and antiviral agent for simultaneous, separate or sequential use in the treatment and/or prevention and/or palliation of cancer
10/06/2011	WO2011085216A3 Use of faah inhibitors for treating parkinson's disease and restless legs syndrome
10/06/2011	WO2011060268A3 Diagnosis and treatment of cancer using histone deacetylase inhibitors and radiolabeled metaiodobenzylguanidine
10/06/2011	WO2011058508A3 Compositions for the treatment of chemoresistant leukaemia and/or of potentially chemoresistant leukaemia
10/06/2011	US20110245784 Anti-infective compositions, methods and systems for treating pathogen-induced disordered tissues
10/06/2011	US20110245501 Substituted Tetracycline Compounds as Synergistic Antifungal Agents
10/06/2011	US20110245270 Nicotinic receptor agonists for the treatment of inflammatory diseases
10/06/2011	US20110245268 Pharmaceutical formulations of substituted azaindoleoxoacetic piperazine derivatives with protease inhibitors
10/06/2011	US20110245202 Pharmaceutical composition for the treatment of rhinitis
10/06/2011	US20110245188 Methods and compositions for the prevention and treatment of inflammatory diseases or conditions
10/06/2011	US20110243930 Compositions and methods for the treatment of immune related diseases
10/06/2011	US20110243890 Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells With a Virus
10/06/2011	US20110243842 Mammalian receptor proteins; related reagents and methods
10/06/2011	CA2796567A1 Composition comprising insulin and herbal oil for transdermal or transmucosal administration
10/06/2011	CA2795456A1 Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling
10/06/2011	CA2795444A1 Staining composition
10/06/2011	CA2794790A1 Parenteral pharmaceutical form which releases aromatse inhibitor and gestagens, for the treatment of endometriosis
10/06/2011	CA2794620A1 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
10/06/2011	CA2794513A1 Perifosine and capecitabine as a combined treatment for cancer
10/06/2011	CA2794443A1 Combination therapy comprising a ccr5 antagonist, a hiv-1 protease inhibitor and a pharmacokinetic enhancer
10/06/2011	CA2793409A1 Method for stimulating the reproductive capacity in a bull, and composition for stimulating the reproductive capacity in a bull
10/05/2011	EP2371839A1 Peptidomimetic protease inhibitors
10/05/2011	EP2371394A1 Composition and method for inhibiting, preventing, or ameliorating complications associated with ingestion of a medicinal, chemical, or biological substance or agent

1 ... 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 ... 1151